Heartware International (HTWR) : Thursdays money flow points at investors jumping to buy the stock on the weakness of price. $17.34 million worth of transactions were on upticks, whereas, the downticks accounted for $2.91 million worth of transactions. The net money flow was a positive $14.43 million and the uptick to downtick ratio was 5.96. The net money flow into the stock was $13.43 million. The lack of interest in trading on downticks shows that the investors dont want to sell their holdings. The upticks accounted for $13.43 million of the total block trades, indicating continued buying interest on weakness, which bodes well for the future of the stock. Heartware International (HTWR) was trading at $57.46, down $0.02 during day. The stock slid -0.03% over the previous days close. For the week, the stock recorded -0.16% over the previous weeks close.
Heartware International (HTWR) : Currently there are 7 street experts covering Heartware International (HTWR) stock. The most bullish and bearish price target for the stock is $58 and $29 respectively for the short term. The average price target of all the analysts comes to $46.43. The estimated standard deviation from the target is $11.72. The stock has recorded a 20-day Moving Average of 40.28% and the 50-Day Moving Average is 68.06%.
Heartware International (NASDAQ:HTWR): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $57.55 and $57.43 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $57.68. The buying momentum continued till the end and the stock did not give up its gains. It closed at $57.53, notching a gain of 0.09% for the day. The total traded volume was 998,049 . The stock had closed at $57.48 on the previous day.
Heartware International, Inc. is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices for patients suffering from advanced heart failure. The HeartWare Ventricular Assist System (HVAD System), which includes a ventricular assist device (VAD) or blood pump, patient accessories and surgical tools, provides circulatory support for patients in the advanced stage of heart failure. The core of the HVAD System is a continuous flow blood pump, the HVAD pump. The HVAD System is designed to be implanted adjacent to the heart, avoiding abdominal surgery, directly adjacent to the heart. The Companys hybrid system is used for suspending the impeller. The impeller is suspended within the pump housing by the opposing forces of passive magnets and hydrodynamic thrust generated by the pump impeller, which circulates a cushion of blood.